Hydrogels for controlled pulmonary delivery

Therapeutic Delivery

Volumn 4, Issue 10, 2013, Pages 1293-1305

  Du, Ju ^a   Du, Ping ^a   Smyth, Hugh D C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885606815     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.90     Document Type: Review

References (130)

1. Einarsson O, Geba GP, Zhou Z et al. Interleukin-11 in respiratory inflammation. Ann. NY Acad. Sci. 762, 89-100; discussion 100-101 (1995).
2. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12(2-3), 151-231 (1995).
3. Balashazy I, Hofmann W, Farkas A, Madas BG. Three-dimensional model for aerosol transport and deposition in expanding and contracting alveoli. Inhal. Toxicol. 20(6), 611-621 (2008).
4. Theravance. Theravance Reports Fourth Quarter and Full Year 2012 Financial Results. Theravance Inc. (2013).
5. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 104(1), 79-90 (2005).
6. Huang WH, Yang ZJ, Wu H, Wong YF, Zhao ZZ, Liu L. Development of liposomal salbutamol sulfate dry powder inhaler formulation. Bio. Pharm. Bull. 33(3), 512-517 (2010).
7. Zeng X, Martin G, Marriott C. The controlled delivery of drugs to the lung. Int. J. Pharm 124(2, 3), 149-165 (1995).
8. Beck-Broichsitter M, Rieger M, Reul R, Gessler T, Seeger W, Schmehl T. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Eur. J. Pharm. Biopharm. 84(1), 106-114, (2012).
9. Biswas S, Deshpande PP, Perche F, Dodwadkar NS, Sane SD, Torchilin VP. Octa-Arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett. 335(1), 191-200 (2013).
10. Monforte V, Lopez-Sanchez A, Zurbano F et al. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J. Heart Lung Transplant 32(3), 313-319 (2013).
11. Murata M, Yonamine T, Tanaka S, Tahara K, Tozuka Y, Takeuchi H. Surface modification of liposomes using polymer-wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration. J. Pharm. Sci. 102(4), 1281-1289 (2013).
12. Seguin J, Brulle L, Boyer R et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int. J. Pharm. 444(1-2), 146-154 (2013).
13. Zhou J, Zhao WY, Ma X et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 34(14), 3626-3638 (2013).
14. Joshi MR, Misra AN. Liposomes of terbutaline sulphate: in vitro and in vivo studies. Indian J. Exp.Bio. 37(9), 881-887 (1999).
15. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS PharmSciTech 9(1), 47-53 (2008).
16. Chougule MB, Padhi BK, Misra A. Nano-liposomal dry powder inhaler of Amiloride Hydrochloride. J. Nanosci. Nanotechnol. 6(9-10), 3001-3009 (2006).
17. Chougule M, Padhi B, Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int J. Nanomedicine 2(4), 675-688 (2007).
18. Thomas DA, Myers MA, Wichert B, Schreier H, Gonzalez-Rothi RJ. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99(5), 1268-1270 (1991).
19. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech 2(4), 25 (2001).
20. Shah SP, Misra A. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv. 11(4), 247-253 (2004).
21. Chougule M, Padhi B, Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomedicine 2(4), 675-688 (2007).
22. Nguyen XC, Herberger JD, Burke PA. Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa. Pharm. Res. 21(3), 507-514 (2004).
23. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 6(3), E482-E486 (2005).
24. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30(10), 1947-1953 (2009).
25. Fiegel J, Fu J, Hanes J. Poly(ether-Anhydride) dry powder aerosols for sustained drug delivery in the lungs. J. Control. Release 96(3), 411-423 (2004).
26. Dunbara C, Scheuchb G, Sommererb K, Delonga M, Vermac A, Batyckya R. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharm. 245(1-2), 179-189 (2002).
27. Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release 121(1-2), 100-109 (2007).
28. Oh YJ, Lee J, Seo JY et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J. Control. Release 150(1), 56-62 (2011).
29. Sivadas N, Cryan SA. Inhalable, bioresponsive microparticles for targeted drug delivery in the lungs. J. Pharm. Pharmacol. 63(3), 369-375 (2011).
30. Upadhyay D, Scalia S, Vogel R et al. Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. Pharm. Res. 29(9), 2456-2467 (2012).
31. Hoare T, Kohane D. Hydrogels in drug delivery: progress and challenges. Polymer 49, 1993-2007 (2008).
32. Gonzalez-Alvarez M, Gonzalez-Alvarez I, Bermejo M. Hydrogels: an interesting strategy for smart drug delivery. Ther. Deliv. 4(2), 157-160 (2013).
33. Adi H, Young PM, Chan HK, Salama R, Traini D. Controlled release antibiotics for dry powder lung delivery. Drug Dev. Ind. Pharm. 36(1), 119-126 (2010).
34. Wichterle O, Lim, D. Hydrophilic gels for biological use. Nature 185, 117-118 (1960).
35. Ruff LE, Mahmoud EA, Sankaranarayanan J et al. Antigen-loaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies. Integr. Biol. (Camb.) 5(1), 195-203 (2013).
36. Huynh CT, Nguyen MK, Jeong IK, Kim SW, Lee DS. Synthesis, characteristics and potential application of poly(b-Amino ester urethane)- based multiblock co-polymers as an injectable, biodegradable and pH/temperature-sensitive hydrogel system. J. Biomater. Sci. Polym. Ed. 23(8), 1091-1106 (2011).
37. Niranjan R, Koushik C, Saravanan S, Moorthi A, Vairamani M, Selvamurugan N. A novel injectable temperature-sensitive zinc doped chitosan/b- glycerophosphate hydrogel for bone tissue engineering. Int. J. Biol. Macromol. 54, 24-29 (2013).
38. Niamlang S, Sirivat A. Electric field assisted transdermal drug delivery from salicylic acid-loaded polyacrylamide hydrogels. Drug Deliv. 16(7), 378-388 (2009).
39. Namdeo M, Bajpai SK, Kakkar S. Preparation of a magnetic-field-sensitive hydrogel and preliminary study of its drug release behavior. J. Biomater. Sci. Polym. Ed. 20(12), 1747-1761 (2009).
40. Perez RA, Won JE, Knowles JC, Kim HW. Naturally and synthetic smart composite biomaterials for tissue regeneration. Adv. Drug Deliv. Rev. (2012).
41. Satarkar NS, Hilt JZ. Magnetic hydrogel nanocomposites for remote controlled pulsatile drug release. J. Control Release 130(3), 246-251 (2008).
42. Singh S, Topuz F, Hahn K, Albrecht K, Groll J. Embedding of active proteins and living cells in redox-sensitive hydrogels and nanogels through enzymatic crosslinking. Angew. Chem. Int. Ed. Engl. 52(10), 3000-3003 (2013).
43. Vemula PK, Wiradharma N, Ankrum JA, Miranda OR, John G, Karp JM. Prodrugs as self-Assembled hydrogels: a new paradigm for biomaterials. Curr. Opin. Biotechnol.(2013).
44. Kushwaha SK, Saxena P, Rai A. Stimuli sensitive hydrogels for ophthalmic drug delivery: a review. Int. J. Pharm. Investig. 2(2), 54-60 (2012).
45. Yoncheva K, Doytchinova I, Tankova L. Preparation and evaluation of isosorbide mononitrate hydrogels for topical fissure treatment. Curr. Drug Deliv. 9(5), 452-458 (2012).
46. Beck-Broichsitter M, Schweiger C, Schmehl T, Gessler T, Seeger W, Kissel T. Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. J. Control. Release 158(2), 329-335 (2012).
47. Ong HX, Traini D, Bebawy M, Young PM. Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm. Res. 28(9), 2327-2338 (2011).
48. Wanakule P, Liu GW, Fleury AT, Roy K. Nano-inside-micro: disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J. Control. Release 162(2), 429-437 (2012).
49. Selvam P, El-Sherbiny IM, Smyth HD. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers. J. Aerosol Med. Pulm. Drug Deliv. 24(1), 25-34 (2011).
50. El-Sherbiny IM, Smyth HD. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-Assembled nanoparticles encapsulated in respirable/ swellable semi-IPN microspheres. Int. J. Pharm. 395(1-2), 132-141 (2010).
51. El-Sherbiny I, Smyth H. Smart magnetically responsive hydrogel nanoparticles prepared by a novel aerosol-Assisted method for biomedical and drug delivery applications. J. Nanomater. 2011, 910539 (2011).
52. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv. 5(6), 629-639 (2008).
53. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J. Aerosol Med. 18(2), 137-182 (2005).
54. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur. Respir. J. 13(5), 1177-1188 (1999).
55. Fiegel J, Brenza T, Hamed R. Controlled transport for pulmonary drug delivery. In:Controlled Pulmonary Drug Delivery . Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 143-163 (2011).
56. Geiser M. Update on macrophage clearance of inhaled micro- And nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 23(4), 207-217 (2010).
57. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657-3666 (2010).
58. Mahmud A, Discher DE. Lung vascular targeting through inhalation delivery: insight from filamentous viruses and other shapes. IUBMB Life 63(8), 607-612 (2011).
59. Balasubramanian SK, Poh KW, Ong CN, Kreyling WG, Ong WY, Yu LE. The effect of primary particle size on biodistribution of inhaled gold nano-Agglomerates. Biomaterials 34(22), 5439-5452 (2013).
60. Gehr P, Geiser M, Hof V, Schürch S, Waber U, Baumann M. Surfactant and inhaled particles in the conducting airways: Structural, stereological, and biophysical aspects. Microsc. Res. Tech. 26(5), 423-436 (1993).
61. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 276(5320), 1868-1871 (1997).
62. Sharma G, Mueannoom W, Buanz AB, Taylor KM, Gaisford S. In vitro characterisation of terbutaline sulphate particles prepared by thermal ink-jet spray freeze drying. Int. J. Pharm. (2013).
63. Watts AB, Wang YB, Johnston KP, Williams RO 3rd. Respirable low-density microparticles formed in situ from aerosolized brittle matrices. Pharm. Res. 30(3), 813-825 (2013).
64. Geiser M, Rothen-Rutishauser B, Kapp N et al. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health Perspect. 113(11), 1555-1560 (2005).
65. Todoroff J, Vanbever R. fate of nanomedicine in the lungs.Curr. Opin. Colloid Interface Sci. 16(3), 246-254 (2011).
66. Beck-Broichsitter M, Gauss J, Packhaeuser CB et al. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int. J. Pharm. 367(1-2), 169-178 (2009).
67. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25(4-5), 427-437 (2005).
68. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269(2), 457-467 (2004).
69. Yang W, Peters JI, Williams RO 3rd. Inhaled nanoparticles-A current review. Int. J. Pharm. 356(1-2), 239-247 (2008).
70. Creutzenberg O, Bellmann B, Korolewitz R et al. Change in agglomeration status and toxicokinetic fate of various nanoparticles in vivo following lung exposure in rats. Inhal. Toxicol. 24(12), 821-830 (2012).
71. Morfeld P, Treumann S, Ma-Hock L, Bruch J, Landsiedel R. Deposition behavior of inhaled nanostructured TiO2 in rats: fractions of particle diameter below 100 nm (nanoscale) and the slicing bias of transmission electron microscopy. Inhal. Toxicol. 24(14), 939-951 (2012).
72. El-Sherbiny IM, Mcgill S, Smyth HD. Swellable microparticles as carriers for sustained pulmonary drug delivery. J. Pharm. Sci. 99(5), 2343-2356 (2010).
73. El-Sherbiny IM, Smyth HD. Poly(ethylene glycol)-carboxymethyl chitosan-based pH-responsive hydrogels: photo-induced synthesis, characterization, swelling, and in vitro evaluation as potential drug carriers. Carbohydr. Res. 345(14), 2004-2012 (2010).
74. Sakagami M, Kinoshita W, Sakon K, Sato J, Makino Y. Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J. Control. Release 80(1-3), 207-218 (2002).
75. Surendrakumar K, Martyn GP, Hodgers EC, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release 91(3), 385-394 (2003).
76. Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J. Control. Release 129(2), 100-106 (2008).
77. Lo YL, Hsu CY, Lin HR. pH-And thermo-sensitive pluronic/poly(acrylic acid) in situ hydrogels for sustained release of an anticancer drug. J. Drug Target. 21(1), 54-66 (2013).
78. Luppi B, Bigucci F, Cerchiara T, Zecchi V. Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin. Drug Deliv. 7(7), 811-828 (2010).
79. Akala EO, Kopeckova P, Kopecek J. Novel pH-sensitive hydrogels with adjustable swelling kinetics. Biomaterials 19(11-12), 1037-1047 (1998).
80. Chen K, Zhang Q, Chen L. Effect of crosslinking degree on hydrogels using surfactant detergent as template. Adv. Mater. Res. 284-286, 1827-1830 (2011).
81. Guvendiren M, Burdick J, Yang S. Kinetic study of swelling-induced surface pattern formation and ordering in hydrogel films with depth-wise crosslinking gradient. Soft Matter 6(9), 2044-2049 (2010).
82. Hennink WE, Van Nostrum CF. Novel crosslinking methods to design hydrogels. Adv. Drug Deliv. Rev. 54(1), 13-36 (2002).
83. Boura C, Menu P, Payan E et al. Endothelial cells grown on thin polyelectrolyte mutlilayered films: an evaluation of a new versatile surface modification. Biomaterials 24(20), 3521-3530 (2003).
84. Boura C, Muller S, Vautier D et al. Endothelial cell-interactions with polyelectrolyte multilayer films. Biomaterials 26(22), 4568-4575 (2005).
85. Schneider GB, English A, Abraham M, Zaharias R, Stanford C, Keller J. The effect of hydrogel charge density on cell attachment. Biomaterials 25(15), 3023-3028 (2004).
86. Kim S, English AE, Kihm KD. Surface elasticity and charge concentration-dependent endothelial cell attachment to copolymer polyelectrolyte hydrogel. Acta Biomater. 5(1), 144-151 (2009).
87. Liu Y, Ibricevic A, Cohen JA et al. Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol. Pharm. 6(6), 1891-1902 (2009).
88. Mobus K, Siepmann J, Bodmeier R. Zinc-Alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying. Eur. J. Pharm. BioPharm. 81(1), 121-130 (2012).
89. Hezaveh H, Muhamad, II. Impact of metal oxide nanoparticles on oral release properties of pH-sensitive hydrogel nanocomposites. Int. J. Biol. Macromol. 50(5), 1334-1340 (2012).
90. Mihaila SM, Gaharwar AK, Reis RL, Marques AP, Gomes ME, Khademhosseini A. Photocrosslinkable k-carrageenan hydrogels for tissue engineering applications .Adv. Healthc. Mater. 2(6), 895-907 (2012).
91. Popa EG, Caridade SG, Mano JF, Reis RL, Gomes ME. Chondrogenic potential of injectable k-carrageenan hydrogel with encapsulated adipose stem cells for cartilage tissue-engineering applications. J. Tissue Eng. Regen. Med. doi: 10.1002/term.1683. (2013) (Epub ahead of print).
92. Popa EG, Gomes ME, Reis RL. Cell delivery systems using alginate-carrageenan hydrogel beads and fibers for regenerative medicine applications. Biomacromolecules 12(11), 3952-3961 (2011).
93. Salgueiro AM, Daniel-Da-Silva AL, Fateixa S, Trindade T. k-carrageenan hydrogel nanocomposites with release behavior mediated by morphological distinct Au nanofillers.Carbohydr. Polym. 91(1), 100-109 (2013).
94. El-Menshawe SF, Hussein AK. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharm. Dev. Technol. (2011).
95. Hezaveh H, Muhamad, II, Noshadi I, Shu Fen L, Ngadi N. Swelling behaviour and controlled drug release from crosslinked k-carrageenan/NaCMC hydrogel by diffusion mechanism. J. Microencapsul. 29(4), 368-379 (2012).
96. Juntapram K, Praphairaksit N, Siraleartmukul K, Muangsin N. Electrosprayed polyelectrolyte complexes between mucoadhesive N,N,N,- trimethylchitosan-homocysteine thiolactone and alginate/carrageenan for camptothecin delivery.Carbohydr. Polym. 90(4), 1469-1479 (2012).
97. Kulkarni RV, Boppana R, Krishna Mohan G, Mutalik S, Kalyane NV. pH-responsive interpenetrating network hydrogel beads of poly(acrylamide)-g- carrageenan and sodium alginate for intestinal targeted drug delivery: synthesis, in vitro and in vivo evaluation. J. Colloid Interface Sci. 367(1), 509-517 (2012).
98. Yamada K, Kamada N, Odomi M et al. Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage. Int. J. Pharm. 293(1-2), 63-72 (2005).
99. Fan H, Dash AK. effect of crosslinking on the in vitro release kinetics of doxorubicin from gelatin implants. Int. J. Pharm. 213(1-2), 103-116 (2001).
100. Podczeck F, Jones B. Pharmaceutical Capsules (2nd Edition). Pharmaceutical Press, London, UK (2004).
101. Tu J, Wang L, Yang J, Fei H, Li X. Formulation and pharmacokinetic studies of acyclovir controlled-release capsules. Drug Dev. Ind. Pharm. 27(7), 687-692 (2001).
102. Rouse JJ, Whateley TL, Thomas M, Eccleston GM. Controlled drug delivery to the lung: Influence of hyaluronic acid solution conformation on its adsorption to hydrophobic drug particles. Int. J. Pharm. 330(1-2), 175-182 (2007).
103. Baier Leach J, Bivens KA, Patrick CW Jr, Schmidt CE. Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnol. Bioeng. 82(5), 578-589 (2003).
104. Park YD, Tirelli N, Hubbell JA. Photopolymerized hyaluronic acid-based hydrogels and interpenetrating networks. Biomaterials 24(6), 893-900 (2003).
105. Shu Z, Liu X, Palumbo Y, Luo FS, Prestwich Y. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25(7-8), 1339-1348 (2004).
106. Yeo Y, Highley CB, Bellas E et al. In situ crosslinkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model. Biomaterials 27(27), 4698-4705 (2006).
107. Morimoto K, Metsugi K, Katsumata H, Iwanaga K, Kakemi M. Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev. Ind. Pharm. 27(4), 365-371 (2001).
108. Gojgini S, Tokatlian T, Segura T. Utilizing cell-matrix interactions to modulate gene transfer to stem cells inside hyaluronic acid hydrogels. Mol. Pharm. 8(5), 1582-1591 (2011).
109. Segura T, Anderson BC, Chung PH, Webber RE, Shull KR, Shea LD. Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern. Biomaterials 26(4), 359-371 (2005).
110. McClellan RO. Particles interactions with the respiratory tract. In:Particle-Lung Interactions. Gehr P, Heyder J (Eds). Marcel Dekker, Inc., NY, USA, 3-63 (2000).
111. Son YJ, Mcconville JT. Advancements in dry powder delivery to the lung. Drug Dev. Ind. Pharm. 34(9), 948-959 (2008).
112. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release 79(1-3), 29-40 (2002).
113. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25(8), 1815-1821 (2008).
114. Makino K, Yamamoto N, Higuchi K, Ohshima H, Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf. B Biointerfaces 27, 33-39 (2003).
115. El-Sherbiny IM, Smyth HD. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol. Pharm. 9(2), 269-280 (2012).
116. Garcia-Contreras L. In vivo animal models for controlled-relase pulmonary drug delivery. In: Controlled Pulmonary Drug Delivery. Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 443-487, (2011).
117. Rossi SE, Erasmus JJ, Mcadams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20(5), 1245-1259 (2000).
118. Singh GJP, Poochikian G. Development and approval of inhaled respiratory drugs: a US regulatory science perspective. In:Controlled Pulmonary Drug Delivery. Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 489-527 (2011).
119. Vandevanter DR, Geller DE. Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review. Med. Devices (Auckl.) 4, 179-188 (2011).
120. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target. 16(9), 639-648 (2008).
121. Chen KH, Mueannoom W, Gaisford S, Kett VL. Investigation into the effect of varying l-leucine concentration on the product characteristics of spray-dried liposome powders. J. Pharm. Pharmacol. 64(10), 1412-1424 (2012).
122. Ehrhardt C, Fiegel J, Fuchs S et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J. Aerosol Med. 15(2), 131-139 (2002).
123. Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers-Toward improved particle characterization in the lung. Pharm. Res. 20(5), 788-796 (2003).
124. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 23(22), 4425-4433 (2002).
125. Gupta V, Ahsan F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE(1), a pulmonary selective vasodilator. Int.J. Pharm. 413(1-2), 51-62 (2011).
126. Gupta V, Davis M, Hope-Weeks LJ, Ahsan F. PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-beta-cyclodextrin (PGE1-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH). Pharm. Res. 28(7), 1733-1749 (2011).
127. Kim I, Byeon HJ, Kim TH et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials 33(22), 5574-5583 (2012).
128. Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, Ainslie KM. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Mol. Pharm. 9(2), 290-298 (2012).
129. Ungaro F, De Rosa G, Miro A, Quaglia F, la Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur. J. Pharm. Sci. 28(5), 423-432 (2006).
130. Ganji F, Vasheghani-Farahani E. Hydrogels in controlled drug delivery systems. Iranian Polym. J. 18(1), 63-88 (2008).